207_Combined course Presentations

Summary

• What we can’t do – 8000 pt trials in unselected breast cancer • What we can do – – New continuum for genome-forward approaches • Representative model systems in parallel + • Small hypothesis-driven trials – New strategies for biomarker-driven clinical trials

• Start broadly (relatively unselected) and learn • Be as critical about assays as you are of drugs – Novel strategies are good, but so are traditional endpoints – Overall survival • Embrace your lab colleagues, molecular pathologists, and statisticians!